Biodesix Inc Revenue Growth Rates (BDSX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biodesix Inc   (NASDAQ: BDSX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

BDSX's Revenue Growth by Quarter and Year

Biodesix Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BDSX/growth
https://api.csimarket.com/api/v1/companies/BDSX/fundamentals
https://api.csimarket.com/api/v1/companies/BDSX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BDSX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 24.04
2nd Quarter June 26.86
1st Quarter March 25.56
FY 76.46

BDSXs Annual Revenue
Biodesix Inc 's Revenue in the fiscal year 2025 $ 88.50 millions
Biodesix Inc 's Revenue in the fiscal year 2024 $ 71.32 millions
Biodesix Inc 's Revenue in the fiscal year 2023 $ 49.09 millions
Biodesix Inc 's Revenue in the fiscal year 2022 $ 38.21 millions
Biodesix Inc 's Revenue in the fiscal year 2021 $ 54.51 millions




BDSX Revenue third quarter 2026 Y/Y Growth Comment
Biodesix Inc reported Revenue increase of 10.43% year on year in the third quarter 2026, to $ 24.04 millions, this is lower than Biodesix Inc 's recent average Revenue improvement of 23.79%.

Looking into third quarter 2026 results within Medical Laboratories industry 22 other companies have achieved higher Revenue growth. While Biodesix Inc ' s Revenue growth of 10.43% ranks overall at the positon no. 2322 in the third quarter 2026.


BDSX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.43 %
2nd Quarter June 34.17 %
1st Quarter March 42.32 %
FY   -

Financial Statements
Biodesix Inc 's third quarter 2026 Revenue $ 24.04 millions BDSX's Income Statement
Biodesix Inc 's third quarter 2025 Revenue $ 21.77 millions Quarterly BDSX's Income Statement


BDSX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -10.5 %
2nd Quarter June 5.09 %
1st Quarter March -11.13 %
FY (Year on Year)   -


Back to BDSX Growth rate Comparisons >> Back to BDSX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #336
Overall #2322

Revenue Y/Y Growth Statistics
High Average Low
127.15 % 23.79 % -59.4 %
(Jun 30 2021)   (Jun 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #336
Overall #2322
Revenue Y/Y Growth Statistics
High Average Low
127.15 % 23.79 % -59.4 %
(Jun 30 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Biodesix Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
422.83 % 26.62 % -75.27 %
(Dec 31 2019)  


BDSX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Biodesix Inc disclosed drop in Revenue from the second quarter by -10.5% to $ 24.04 millions, from $ 26.86 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Biodesix Inc 's Revenue growth quarter on quarter, overall rank is 1149.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #11
Healthcare Sector #169
Overall #1149
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #11
Healthcare Sector #169
Overall #1149
Revenue Q/Q Growth Statistics
High Average Low
422.83 % 26.62 % -75.27 %
(Dec 31 2019)  


BDSX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Biodesix Inc disclosed drop in Revenue from the second quarter by -10.5% to $ 24.04 millions, from $ 26.86 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Biodesix Inc 's Revenue growth quarter on quarter, overall rank is 1149.


Biodesix Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 105.21
Y / Y Revenue Growth (TTM) 31.23 %
Year on Year Revenue Growth Overall Ranking # 656
Seqeuential Revenue Change (TTM) 2.21 %
Seq. Revenue Growth (TTM) Overall Ranking # 2336


Cumulative Revenue growth Comment
Assuming the Biodesix Inc 's fiscal year would have ended in Sep 30 2026, Biodesix Inc would have reprted above average annual Revenue rise of 31.23% year on year, of $ 105 millions.
This marks a slow-down of the companys growth trends and from the 34.46% improvement in Jun 30 2026.

In the Healthcare sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 364 to 656.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 138
Overall # 656

Revenue TTM Y/Y Growth Statistics
High Average Low
127.15 %
 23.79 %
-59.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2336
Cumulative Revenue growth Comment
Assuming the Biodesix Inc 's fiscal year would have ended in Sep 30 2026, Biodesix Inc would have reprted above average annual Revenue rise of 31.23% year on year, of $ 105 millions.
This marks a slow-down of the companys growth trends and from the 34.46% improvement in Jun 30 2026.

In the Healthcare sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 364 to 656.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 138
Overall # 656

Revenue TTM Y/Y Growth Statistics
High Average Low
127.15 %
23.79 %
-59.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2336




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BDSX's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions


About Biodesix Inc Revenue Growth Rates (BDSX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biodesix Inc (CIK 1439725).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-449763
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biodesix Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.